
The perfect Sicilian dish to make use of delicious winter produce
She was previously the head chef at Fred's in Paddington before she stepped down last year to focus on other projects.
Danielle is cooking Sicilian caponata which is a dish made with roasted pumpkin and fennel and topped with fresh mozzarella.
Recipe below:
Fennel and pumpkin caponata with mozzarella
Makes: Enough to serve 4
Active time: 25 minutes
Inactive time: 40 minutes
Ingredients
Quarter of a large butternut pumpkin (squash) (or half a small honeynut pumpkin)
¼ cup (60 ml) extra-virgin olive oil, plus extra for roasting vegetables
1 medium fennel bulb
Half a brown onion, diced small
1 x 400 g (14 oz) tin cherry tomatoes, rinsed, or 250 g (9 oz) fresh cherry tomatoes
2 tablespoons pine nuts, toasted
2 tablespoons currants
1 tablespoon salted capers, rinsed
1/3 cup (50 g) pitted green olives (e.g. gordal or green Sicilian)
1½ tablespoons white (granulated) sugar
3 tablespoons white wine vinegar
1 stalk celery, diced small
1 ball (about 110 g/3¾ oz) fresh cow's or buffalo milk mozzarella (see note)
Fine sea salt
To serve
Good-quality extra-virgin olive oil
Flaked sea salt
Freshly cracked black pepper
Method
I am very drawn to the Sicilian flavour profile of sweet, sour, salty and oily. Caponata is the perfect embodiment of this combination. This dish is best served at room temperature, with good crusty bread or focaccia to mop everything up.
Preheat your oven to 180°C (350°F) and line a baking tray with baking paper.
Peel and deseed the pumpkin and cut it into 3–4 cm (1¼–1½ inch) pieces. Toss the pumpkin with some of the extra olive oil and sprinkle with salt, then place it on the baking tray. Cut the fennel into eight wedges then toss with more of the extra olive oil and sprinkle with salt, then place on the same tray, next to the pumpkin. Roast for 30–40 minutes, until both are golden brown and tender.
Set a large sauté pan (with a lid) over a medium heat and add the ¼ cup (60 ml) of olive oil, the onion and a pinch of salt and cook until the onion is soft and sweet and beginning to brown. Add the tomatoes, pine nuts, currants, capers, olives, sugar and vinegar and cook together on a low heat for about 8 minutes. Turn off the heat.
When the pumpkin and fennel are ready, set the sauté pan with the tomato mix over a low heat and add the celery. Cook for 1 minute, then add the roasted pumpkin and fennel to the pan and stir to combine. Cook for a further minute, then turn off the heat and place the lid on the pan. Let it sit and steam together as it cools. Taste for seasoning and adjust with more salt and vinegar if needed.
Serve the caponata at room temperature with the torn mozzarella on top, finishing with a drizzle of good-quality olive oil, a sprinkle of flaked sea salt and a crack of pepper.
Note: Mozzarella is made with either cow's milk or buffalo milk. Cow's milk mozzarella, known as fior di latte, literally means 'flower of milk', indicating its purity, and the name is used to describe both mozzarella and gelato. Mozzarella made with buffalo milk, known as di latte di bufala, has a creamier, more tangy flavour than the more traditional cow's milk mozzarella.
Seasonal adjustment: In summer, swap the pumpkin and fennel for a large purple eggplant (aubergine) for a more traditional caponata.
As with many Sicilian dishes, caponata has drawn its ingredients from across the Mediterranean. It is also a dish that traditionally travels, with the vegetables being bought fresh at port and the sailors preserving them with vinegar and sugar while at sea.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
The Cigna Group Reports Strong Second Quarter 2025 Results, Reaffirms 2025 Adjusted EPS Outlook
Total revenues for the second quarter 2025 increased 11% to $67.2 billion Shareholders' net income for the second quarter 2025 was $1.5 billion, or $5.71 per share Adjusted income from operations1 for the second quarter 2025 was $1.9 billion, or $7.20 per share Reaffirms 2025 outlook for adjusted income from operations1,2 of at least $29.60 per share2 BLOOMFIELD, Conn., July 31, 2025 /PRNewswire/ -- Global health company The Cigna Group (NYSE: CI) today reported strong second quarter 2025 results, reflecting continued growth and solid performance across its diverse portfolio of businesses. "Listening, adapting, and innovating to meet the evolving needs of our patients, customers, and clients enables us to deliver meaningful value," said David M. Cordani, chairman and CEO of The Cigna Group. "Our performance in the second quarter reflects our disciplined execution and the strength of our business mix." Shareholders' net income for second quarter 2025 was $1.5 billion, or $5.71 per share, and compares with $1.5 billion, or $5.45 per share, for second quarter 2024. The Cigna Group's adjusted income from operations1 for second quarter 2025 was $1.9 billion, or $7.20 per share, compared with $1.9 billion, or $6.72 per share, for second quarter 2024. A reconciliation of shareholders' net income to adjusted income from operations1 is provided on the following page and on Exhibit 1 of this earnings release. CONSOLIDATED HIGHLIGHTS The following table includes highlights of results and reconciliations of total revenues to adjusted revenues3 and shareholders' net income to adjusted income from operations1: Consolidated Financial Results (dollars in millions): Three Months Ended Six MonthsEndedJune 30, March 31, June 30,2025 2024 2025 2025Total Revenues $ 67,178 $ 60,523 $ 65,502 $ 132,680 Net Investment Results from Equity Method Investments3 (44) (53) (50) (94) Adjusted Revenues3 $ 67,134 $ 60,470 $ 65,452 $ 132,586Consolidated Earnings, net of taxes Shareholders' Net Income $ 1,532 $ 1,548 $ 1,323 $ 2,855 Net Investment (Gains)1 (103) (20) (48) (151) Amortization of Acquired Intangible Assets1 330 317 336 666 Special Items1 171 64 229 400 Adjusted Income from Operations1 $ 1,930 $ 1,909 $ 1,840 $ 3,770Shareholders' Net Income, per share $ 5.71 $ 5.45 $ 4.85 $ 10.55 Adjusted Income from Operations1, per share $ 7.20 $ 6.72 $ 6.74 $ 13.94 Total revenues for second quarter 2025 increased 11% relative to second quarter 2024, primarily driven by Evernorth Health Services and includes growth of existing client relationships and strong specialty pharmacy growth. Adjusted income from operations1 for second quarter 2025 increased 1% relative to second quarter 2024, reflecting strong growth in Evernorth Health Services and improvement in Corporate, partially offset by expected higher stop loss medical costs in Cigna Healthcare. The SG&A expense ratio4 and adjusted SG&A expense ratio4 were 5.1% and 4.9%, respectively, for second quarter 2025, compared to 6.1% and 6.0%, respectively, in second quarter 2024, reflecting business mix shift and strong revenue growth. CUSTOMER RELATIONSHIPS The following table summarizes The Cigna Group's medical customers and overall customer relationships: Customer Relationships (in thousands):As of the Periods EndedJune 30, March 31, December 31,2025 2024 2025 2024Total Pharmacy Customers5 121,892 122,470 122,283 118,304U.S. Healthcare 16,355 17,404 16,364 17,502 International Health 1,691 1,639 1,679 1,645 Total Medical Customers5 18,046 19,043 18,043 19,147Behavioral Care 23,852 23,816 23,416 23,932 Dental 18,446 18,339 18,466 18,258 Medicare Part D — 2,564 — 2,571Total Customer Relationships5 182,236 186,232 182,208 182,212 Total customer relationships5 at June 30, 2025 were 182.2 million. Excluding the impact of the HCSC transaction6, total customer relationships5 increased 2% from December 31, 2024. Total pharmacy customers5 at June 30, 2025 increased 3% from December 31, 2024 to 121.9 million due to new sales and the continued expansion of relationships. Total medical customers5 at June 30, 2025 decreased 6% from December 31, 2024 to 18.0 million, primarily reflecting the impact of the HCSC transaction6. Excluding the impact of the HCSC transaction6, total medical customers5 as of June 30, 2025 were consistent relative to December 31, 2024. HIGHLIGHTS OF SEGMENT RESULTS See Exhibit 1 for a reconciliation of adjusted income from operations1 to shareholders' net income. Evernorth Health Services This segment includes the Pharmacy Benefit Services and Specialty and Care Services operating segments, which provide independent and coordinated health solutions and capabilities to enable the health care system to work better and help people live healthier lives. Pharmacy Benefit Services drives high-quality, cost-effective pharmacy care through various services such as drug claim adjudication, retail pharmacy network administration, benefit design consultation, drug utilization review, drug formulary management and access to our home delivery pharmacy. Specialty and Care Services provides specialty drugs for the treatment of complex and rare diseases, specialty distribution of pharmaceuticals and medical supplies, as well as clinical programs to help our clients drive better whole-person health outcomes through care services. Financial Results (dollars in millions):Three Months Ended Six Months EndedJune 30, March 31, June 30,2025 2024 2025 2025 Total Adjusted Revenues Pharmacy Benefit Services $ 31,954 $ 26,630 $ 29,742 $ 61,696 Specialty and Care Services $ 25,871 $ 22,918 $ 23,939 $ 49,810 Adjusted Revenues3 $ 57,825 $ 49,548 $ 53,681 $ 111,506 Adjusted Income from Operations, Pre-Tax Pharmacy Benefit Services $ 833 $ 816 $ 544 $ 1,377 Specialty and Care Services $ 863 $ 803 $ 890 $ 1,753 Adjusted Income from Operations, Pre-Tax1 $ 1,696 $ 1,619 $ 1,434 $ 3,130 Margin, Pre-Tax7 2.9 % 3.3 % 2.7 % 2.8 % Evernorth Health Services second quarter 2025 adjusted revenues3 and adjusted income from operations, pre-tax1, increased 17% and 5%, respectively, relative to second quarter 2024. For Pharmacy Benefit Services second quarter 2025 relative to second quarter 2024: Adjusted revenues3 increased 20% reflecting strong organic growth, including the growth of existing client relationships, and new business. Adjusted income from operations, pre-tax1, increased 2% reflecting continued affordability improvements, partially offset by initiatives to support business growth. For Specialty and Care Services second quarter 2025 relative to second quarter 2024: Adjusted revenues3 increased 13% reflecting strong specialty volume growth. Adjusted income from operations, pre-tax1, increased 7% reflecting strong organic growth in specialty businesses, including increased biosimilar adoption. Year-over-year growth was also impacted by lower net investment income in second quarter 2025 compared to second quarter 2024. Cigna Healthcare This segment includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical and coordinated solutions to clients and customers. U.S. Healthcare provides medical plans and other benefits and solutions for insured and self-insured clients as well as individual health plans. International Health provides health care solutions in our international markets, as well as health solutions for globally mobile individuals and employees of multinational organizations. U.S. Healthcare included the Medicare and related businesses until the divestiture of such businesses to Health Care Services Corporation ("HCSC")6 on March 19, 2025. Financial Results (dollars in millions):Three Months Ended Six Months EndedJune 30, March 31, June 30,2025 2024 2025 2025Adjusted Revenues3,8 $ 10,754 $ 13,143 $ 14,482 $ 25,236 Adjusted Income from Operations, Pre-Tax1 $ 1,094 $ 1,204 $ 1,287 $ 2,381 Margin, Pre-Tax7 10.2 % 9.2 % 8.9 % 9.4 % Second quarter 2025 adjusted revenues3,8 decreased 18% relative to second quarter 2024, primarily reflecting the impact of the HCSC transaction6,8. Excluding the impact of the HCSC transaction6,8, second quarter 2025 adjusted revenues3,8 would have increased 7% relative to second quarter 2024, primarily driven by premium rate increases to cover expected increases in medical costs. Second quarter 2025 adjusted income from operations, pre-tax1, decreased 9% relative to second quarter 2024, primarily driven by a higher MCR4. The Cigna Healthcare MCR4 was 83.2% for second quarter 2025 compared to 82.3% for second quarter 2024, primarily due to expected higher stop loss medical costs. Cigna Healthcare net medical costs payable9 was $4.49 billion at June 30, 2025 which increased relative to $4.37 billion at March 31, 2025, and decreased relative to $5.04 billion at June 30, 2024. Cigna Healthcare net medical costs payable9 at June 30, 2024 included $895 million from businesses included in the HCSC transaction6. Favorable prior year reserve development on a gross pre-tax basis was $297 million and $284 million for the six months ended June 30, 2025 and 2024, respectively. Corporate and Other Operations Corporate reflects interest expense, amounts not allocated to operating segments and includes intersegment eliminations. Other Operations is comprised of Corporate Owned Life Insurance ("COLI"), the Company's run-off operations and other non-strategic businesses. Financial Results (dollars in millions):Three Months Ended Six Months EndedJune 30, March 31, June 30,2025 2024 2025 2025Adjusted (Loss) from Operations, Pre-Tax1 $ (357) $ (451) $ (411) $ (768) 2025 OUTLOOK2 The Cigna Group's outlook2 for full year 2025 consolidated adjusted income from operations1,2 is at least $29.60 per share2. Additionally, this outlook includes the impact of expected future share repurchases and anticipated 2025 dividends. (dollars in millions, except where noted and per share amounts) 2025 Consolidated Metrics Projection for Full Year Ending December 31, 2025Adjusted Income from Operations, per share1,2 at least $29.60Evernorth Adjusted Income from Operations, Pre-Tax1,2 at least $7,200Cigna Healthcare Adjusted Income from Operations, Pre-Tax1,2 at least $4,125Cigna Healthcare Medical Care Ratio2,4 83.2% to 84.2% The foregoing statements represent the Company's current estimates of The Cigna Group's 2025 consolidated and segment adjusted income from operations1,2 and other key metrics as of the date of this release. Actual results may differ materially depending on a number of factors. Investors are urged to read the Cautionary Note Regarding Forward-Looking Statements included in this release. Management does not assume any obligation to update these estimates. This quarterly earnings release and the Quarterly Financial Supplement are available on The Cigna Group's website in the Investor Relations section ( Management will be hosting a conference call to review second quarter 2025 results and discuss full year 2025 outlook beginning today at 8:30 a.m. ET. A link to the conference call is available in the Investor Relations section of The Cigna Group's website located at The call-in numbers for the conference call are as follows: Live Call (888) 566-1889 (Domestic) (773) 799-3989 (International) Passcode: 07312025 Replay (800) 835-8067 (Domestic) (203) 369-3354 (International) It is strongly suggested you dial in to the conference call by 8:15 a.m. ET. About The Cigna Group The Cigna Group (NYSE: CI) is a global health company committed to creating a better future built on the vitality of every individual and every community. We relentlessly challenge ourselves to partner and innovate solutions for better health. The Cigna Group includes products and services marketed under Evernorth Health Services, Cigna Healthcare, or its subsidiaries. The Cigna Group maintains sales capabilities in more than 30 markets and jurisdictions, and has more than 180 million customer relationships around the world. Learn more at Notes: 1. Adjusted income (loss) from operations is a principal financial measure of profitability used by The Cigna Group's management because it presents the underlying results of operations of the Company's businesses and facilitates analysis of trends in underlying revenue, expenses and shareholders' net income. Adjusted income (loss) from operations is defined as shareholders' net income (or income before income taxes less pre-tax income (loss) attributable to noncontrolling interests for the segment metric) excluding net investment gains/losses, amortization of acquired intangible assets and special items. The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. Consolidated adjusted income (loss) from operations is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, shareholders' net income. See Exhibit 1 for a reconciliation of consolidated adjusted income from operations to shareholders' net income. 2. Management is not able to provide a reconciliation of adjusted income from operations to shareholders' net income, on a forward-looking basis because it is unable to predict, without unreasonable effort, certain components thereof including (i) future net investment results and (ii) future special items. These items are inherently uncertain and depend on various factors, many of which are beyond The Cigna Group's control. As such, any associated estimate and its impact on shareholders' net income and total revenues could vary materially. The Company's outloo excludes the potential effects of any other business combinations that may occur after the date of this earnings release. The Company's outlook includes the potential effects of expected future share repurchases and anticipated 2025 dividends. The timing and actual number of shares repurchased will depend on a variety of factors, including price, general business and market conditions, and alternate uses of capital. The share repurchase program may be effected through open market purchases in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended, including through Rule 10b5-1 trading plans, or privately negotiated transactions. The program may be suspended or discontinued at any time. 3. Adjusted revenues is used by The Cigna Group's management because it facilitates analysis of trends in underlying revenue. The Company defines adjusted revenues as total revenues excluding the following adjustments: special items and The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. We exclude these items from this measure because management believes they are not indicative of past or future underlying performance of the business. Adjusted revenues is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, total revenues. See Exhibit 1 for a reconciliation of consolidated adjusted revenues to total revenues. 4. Operating ratios are defined as follows: The Cigna Healthcare medical care ratio ("MCR") represents medical costs as a percentage of premiums for all Cigna Healthcare risk products provided through guaranteed cost or experience-rated funding arrangements. Changes in percentages may be expressed in basis points ("bps"). SG&A expense ratio on a GAAP basis for the second quarter 2025 represents enterprise selling, general and administrative expenses of $3,433 million as a percentage of total revenue of $67.2 billion at a consolidated level. SG&A expense ratio on a GAAP basis for the second quarter 2024 represents enterprise selling, general and administrative expenses of $3,684 million as a percentage of total revenue of $60.5 billion at a consolidated level. Adjusted SG&A expense ratio for the second quarter 2025 represents enterprise selling, general and administrative expenses of $3,271 million excluding special items of $162 million as a percentage of adjusted revenue at a consolidated level. Adjusted SG&A expense ratio for the second quarter 2024 represents enterprise selling, general and administrative expenses of $3,621 million excluding special items of $63 million as a percentage of adjusted revenue at a consolidated level. 5. Customer relationships are defined as follows: Total medical customers includes individuals who meet any one of the following criteria: (i) are covered under a medical insurance policy, managed care arrangement, or administrative services agreement issued by Cigna Healthcare; (ii) have access to Cigna Healthcare's provider network for covered services under their medical plan; or (iii) have medical claims that are administered by Cigna Healthcare. Total customer relationships and total medical customers as of December 31, 2024, excluding the impact of the HCSC transaction3, were 179,712 thousand and 18,055 thousand, respectively. 6. On March 19, 2025, the company completed the sale (the "HCSC transaction") of its Medicare Advantage, Medicare Individual Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits, and CareAllies businesses to Health Care Services Corporation ("HCSC"). 7. Margin, pre-tax, is calculated by dividing adjusted income (loss) from operations, pre-tax by adjusted revenues for each segment. 8. The Cigna Group owns noncontrolling interests in certain operating joint ventures. As such, the adjusted revenues for the Cigna Healthcare segment only include the Company's share of the joint ventures' earnings reported in Fees and Other Revenues using the equity method of accounting under GAAP. Set forth below is a table that presents the impact of the HCSC transaction on Cigna Healthcare Adjusted Revenues for the periods presented. Management believes that the presentation of this measure is useful to investors because it permits a comparison of the Company's go-forward business across periods. Financial Results (dollars in millions):Three Months Ended Six Months EndedJune 30, March 31, June 30,2025 2024 2025 2025Cigna Healthcare Adjusted Revenues3 $ 10,754 $ 13,143 $ 14,482 $ 25,236 Less: U.S. Healthcare - divested businesses revenues — 3,137 3,850 3,850 Cigna Healthcare Adjusted Revenues3 excluding U.S. Healthcare - divested businesses revenues $ 10,754 $ 10,006 $ 10,632 $ 21,386 9. Medical costs payable within the Cigna Healthcare segment are presented net of reinsurance and other recoverables. The gross medical costs payable balance was $4.64 billion as of June 30, 2025, $4.51 billion as of March 31, 2025, and $5.20 billion as of June 30, 2024. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This press release, and oral statements made in connection with this release, may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on The Cigna Group's current expectations and projections about future trends, events and uncertainties. These statements are not historical facts. Forward-looking statements may include, among others, statements concerning our projected outlook for 2025 (including adjusted revenues; adjusted income from operations, including on a per share, and segment basis; adjusted SG&A expense ratio; adjusted effective tax rate; cash flow from operations; capital expenditures; shareholder dividends; weighted average shares outstanding; medical care ratio; and total medical customers); future financial or operating performance, including our ability to improve the health and vitality of those we serve; future growth, business strategy and strategic or operational initiatives, including our ability to successfully implement actions across our business to strengthen our platform and build a more sustainable model for healthcare; economic, regulatory or competitive environments; capital deployment plans and amounts available for future deployment; our prospects for growth in the coming years; and other statements regarding The Cigna Group's future beliefs, expectations, plans, intentions, liquidity, cash flows, financial condition or performance. You may identify forward-looking statements by the use of words such as "believe," "expect," "project," "plan," "intend," "anticipate," "estimate," "predict," "potential," "may," "should," "will" or other words or expressions of similar meaning, although not all forward-looking statements contain such terms. Forward-looking statements are subject to risks and uncertainties, both known and unknown, that could cause actual results to differ materially from those expressed or implied in forward-looking statements. Such risks and uncertainties include, but are not limited to: our ability to achieve our strategic and operational initiatives; our ability to adapt to changes in an evolving and rapidly changing industry; our ability to compete effectively, differentiate our products and services from those of our competitors and maintain or increase market share; price competition, inflation and other pressures that could compress our margins or result in premiums that are insufficient to cover the cost of services delivered to our customers; the potential for actual claims to exceed our estimates related to expected medical claims; our ability to develop and maintain satisfactory relationships with health care payors, physicians, hospitals, other health service providers and with producers and consultants; our ability to maintain relationships with one or more key pharmaceutical manufacturers or if payments made or discounts provided decline; changes in the pharmacy provider marketplace or pharmacy networks; changes in drug pricing or industry pricing benchmarks; our ability to invest in and properly maintain our information technology and other business systems; our ability to prevent or contain effects of a potential cyberattack or other privacy or data security incident; risks related to our use of artificial intelligence and machine learning; political, legal, operational, regulatory, economic and other risks that could affect our multinational operations, including currency exchange rates; risks related to strategic transactions and realization of the expected benefits of such transactions, as well as integration or separation difficulties or underperformance relative to expectations which could lead to an impairment charge; dependence on success of relationships with third parties; risk of significant disruption within our operations or among key suppliers or third parties; potential liability in connection with managing medical practices and operating pharmacies, onsite clinics and other types of medical facilities; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; uncertainties surrounding participation in government-sponsored programs and providing services to payors who participate in government-sponsored programs; the outcome of litigation, regulatory audits and investigations; compliance with applicable privacy, security and data laws, regulations and standards; potential failure of our prevention, detection and control systems; unfavorable economic and market conditions, the risk of a recession or other economic downturn and resulting impact on employment metrics, stock market or changes in interest rates; risks related to a downgrade in financial strength ratings of our insurance subsidiaries; the impact of our significant indebtedness and the potential for further indebtedness in the future; credit risk related to our reinsurers; as well as more specific risks and uncertainties discussed in our most recent report on Form 10-K and subsequent reports on Forms 10-Q and 8-K available through the Investor Relations section of You should not place undue reliance on forward-looking statements, which speak only as of the date they are made, are not guarantees of future performance or results, and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. The Cigna Group undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required by law. THE CIGNA GROUPExhibit 1 COMPARATIVE SUMMARY OF FINANCIAL RESULTS (unaudited) Three Months Ended Six Months EndedThree Months Ended June 30, June 30,March 31, (Dollars in millions, except per share amounts)2025 2024 2025 20242025REVENUESPharmacy revenues$ 53,649 $ 45,101 $ 102,282 $ 87,137 $ 48,633 Premiums9,156 11,454 21,892 23,057 12,736 Fees and other revenues4,137 3,647 8,032 6,973 3,895 Net investment income236 321 474 611 238 Total revenues67,178 60,523 132,680 117,778 65,502 Net investment results from certain equity method investments(44) (53) (94) (61) (50) Adjusted revenues (1)$ 67,134 $ 60,470 $ 132,586 $ 117,717 $ 65,452Shareholders' net income$ 1,532 $ 1,548 $ 2,855 $ 1,271 $ 1,323 Pre-tax adjusted income (loss) from operations by segment Evernorth Health Services$ 1,696 $ 1,619 $ 3,130 $ 2,979 $ 1,434 Cigna Healthcare1,094 1,204 2,381 2,544 1,287 Corporate and Other Operations(357) (451) (768) (842) (411) Adjusted income tax expense (503) (463) (973) (897) (470) Consolidated after-tax adjusted income from operations$ 1,930 $ 1,909 $ 3,770 $ 3,784 $ 1,840Weighted average shares (in thousands)268,154 284,052 270,540 286,884 272,953 Common shares outstanding (in thousands)266,901 279,520 269,773 SHAREHOLDERS' EQUITY at June 30,$ 40,214 $ 41,332SHAREHOLDERS' EQUITY PER SHARE at June 30,$ 150.67 $ 147.87Three Months EndedSix Months EndedThree MonthsEndedJune 30,June 30,March 31,20252024202520242025 (Dollars in millions, except per share amounts) Pre-tax After-taxPre-tax After-taxPre-tax After-taxPre-tax After-taxPre-tax After-taxSHAREHOLDERS' NET INCOMEShareholders' net income$ 1,532 $ 1,548 $ 2,855 $ 1,271 $ 1,323 Adjustments to reconcile adjusted income from operations Net investment (gains) losses (2) $ (96) (103)$ (5) (20)$ (144) (151)$ 1,823 1,807$ (48) (48) Amortization of acquired intangible assets 422 330420 317844 666843 639422 336 Special Items Strategic optimization program 129 98— —344 261— —215 163 Integration and transaction-related costs 74 5663 47290 220100 76216 164 (Gain) loss on sale of businesses — —— —(41) (115)19 (43)(41) (115) Deferred tax expenses, net — 17— 17— 34— 34— 17 Adjusted income from operations (3)$ 1,930 $ 1,909 $ 3,770 $ 3,784 $ 1,840DILUTED EARNINGS PER SHAREShareholders' net income$ 5.71 $ 5.45 $ 10.55 $ 4.43 $ 4.85 Adjustments to reconcile to adjusted income from operations Net investment (gains) losses (2) $ (0.36) (0.38)$ (0.02) (0.07)$ (0.53) (0.56)$ 6.36 6.30$ (0.18) (0.18) Amortization of acquired intangible assets 1.57 1.231.48 1.113.12 2.472.94 2.231.54 1.23 Special Items Strategic optimization program 0.48 0.37— —1.27 0.97— —0.79 0.60 Integration and transaction-related costs 0.28 0.210.22 0.171.07 0.810.34 0.260.79 0.60 (Gain) loss on sale of businesses — —— —(0.15) (0.43)0.07 (0.15)(0.15) (0.42) Deferred tax expenses, net — 0.06— 0.06— 0.13— 0.12— 0.06 Adjusted income from operations (3)$ 7.20 $ 6.72 $ 13.94 $ 13.19 $ 6.74 (1)Adjusted revenues is defined as total revenues excluding the following adjustments: special items and The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. These items are excluded because they are not indicative of past or future underlying performance of our businesses. (2)Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income. (3)Adjusted income (loss) from operations is defined as shareholders' net income (or income before income taxes less pre-tax income (loss) attributable to noncontrolling interests for the segment metric) excluding the following adjustments: net investment gains/losses, amortization of acquired intangible assets and special items. The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. INVESTOR RELATIONS CONTACT:Ralph MEDIA CONTACT:Justine View original content to download multimedia: SOURCE The Cigna Group
Yahoo
22 minutes ago
- Yahoo
Lopez: She left college to conquer tennis. At 81, Billie Jean King is back, chasing a degree
Everyone reaches a point in life when it's OK to sink into the easy chair, prop up their feet and take a deep breath. Apparently, no one has told this to Billie Jean King. Since the time she was a child in Long Beach, raised by a firefighter and homemaker, King has been filling history books. She won more singles and doubles championships at Wimbledon than anyone before or since, and she was the No. 1 female tennis player in the world. She's been carrying a flag, for decades, for gender equality and LGBTQ+ rights in sports and society. She was awarded the Presidential Medal of Freedom and the Congressional Gold Medal. Fifty million people tuned in on their televisions one evening in 1973 and watched her whip Bobby Riggs in a tennis challenge billed as 'The Battle of the Sexes." But King's resume, which would stretch from one end of Wimbledon's Center Court to the other and keep going, is missing one thing, and that was bugging her. The omission came up last year in a conversation she was having with the staff of her New York-based consulting, investing and marketing company. (Yes, she still runs a business and a foundation promoting education, leadership and activism.) 'I hate not finishing,' she recalls telling her colleagues. They asked what she meant. 'I haven't finished college,' she told them. 'And, you know, I should finish.' Read more: Billie Jean King looked at Hollywood Walk of Fame stars as a kid. Tennis icon now has her own Yeah, what a slacker. In the spring this year, at the age of 81, Billie Jean King went back to school, chasing not a trophy, or a cup, or a medal, but a degree. And there was no doubt in her mind about where she would enroll — at the very school where she began her college education in the '60s before going pro. The school that has a statue of her near the courts where she used to smack tennis balls around. Cal State L.A. (Would anyone be surprised if she went out for the tennis team?) Lots of people start college and then take a pause. King's lasted 60 years. The woman who keeps making history is now majoring in it. She's taken several courses this year and will soon begin the fall semester as a senior, on track to graduate in the spring with a bachelor's degree in history. 'I'm having a great time,' she told me Wednesday by video link from her home in New York. King isn't strolling campus with a backpack and hanging with fellow students at the library and food court. Her business ventures keep her on the road and mostly on the East Coast, so she takes her classes remotely, usually one- on-one with professors who helped her craft a flexible schedule. She's also earned course credit for her interaction with other CSULA students who have taken a somewhat circuitous route to a bachelor's degree — they're enrolled in Cal State L.A.'s Prison Graduation Initiative while serving time. Read more: Excerpt: Billie Jean King on growing up in Long Beach and saving up $8.29 for her first racket After I interviewed King, she spoke remotely with 32 inmate/students at the maximum-security state prison in Lancaster and sent me an email when she was done. "They have made a commitment to improving their lives through education," she said, and "getting their degree will be life-changing for them." A few months ago, she did the same hookup with inmate/students at the California Institute for Women in Chino. 'I wanted to know their stories,' King told me, adding that she told them to work together toward shared goals. She also asked them what they miss most while in prison. The answers, she said, were quite candid. 'One woman took total ownership. She said, 'I miss my children. I miss being free…. I even miss the husband that I killed.' Yes, that does sound pretty candid. King's fall classes will include U.S. and Latin American history. Her favorite spring semester class was historiography, a study of how historians research and interpret the past. "It's like the history of history," King said. I felt like I wouldn't be doing my job if I didn't ask about her GPA. King said she hasn't gotten a report card yet, but says she's taking no shortcuts on assignments, and the homework load is not exactly light. 'I just read like crazy all the time,' said King, who has turned her paper chase into something of a cause. In social media posts extolling the value of continuing to engage, learn and grow — at any age — she sits next to a stack of assigned texts, including 'Contested Histories in Public Space' and 'Fighting Over the Founders.' She's also reading books on Title IX, the civil rights law that banned sexual discrimination in federally funded education programs. On that subject, King is more teacher than student. She was an early and persistent advocate for Title IX, and testified before Congress. 'The thing they like,' she said of her professors, 'is that I have lived some of these historical moments.' King said she hasn't been shy about pointing out what she considers errors in the telling of history she was a part of. 'It drives me crazy.' In that regard, and other obvious ways, King is not the prototypical Cal State L.A. student. "It's been 50 years of changing the world," communications studies department Chair David Olsen said of King's achievements. But in other ways, she's typical. I used to teach a class at CSULA, and most of my students were jugglers. They had jobs and families, and with so many other responsibilities and pursuits, they weren't in and out in four years. Some, like King, took a break but circled back. "Oh, I guess I am like them," King said. "It's never too late to return, and it's never too late to finish," Olsen said. "The coming back, to me, is what's so important and inspiring" — especially because finishing her education was an elective rather than a requirement. "To be a lifelong learner — that's an important lesson," said Scott Wells, chair of the CSULA history department. "She doesn't need to do this for career reasons or economic reasons. It's a reminder that higher education is not merely getting technical skills or a piece of paper for a job opportunity.... When she posted on social media, 'Here are the books I'm reading,' it's a way of saying that books are important and people should care about history." I asked King, who's been at the forefront of so many social justice movements, what it's like to live through this moment in political and cultural history, in which many of the gains she fought for are under threat, and in which our heritage is depicted on government websites as white, covered wagon pioneers. Read more: This day in sports: Billie Jean King wins her first of six Wimbledon singles titles "How about slavery?" King said. "Look at athletes who tried to travel. Look at Jackie Robinson. Look at Althea Gibson. "I learned white history as a kid, and then I realized ... the people who were here first were our Indigenous people. " History repeats itself, King said, and "it's repeating itself again now" in disconcerting ways. "I mean, we were fighting so hard ... for Roe vs. Wade, and we got it through," she said of the landmark Supreme Court decision on women's reproductive rights in 1973. "And now we're going backwards again." Her job in her 80s, King said, is not to lead the resistance, but to ask the next generation what it wants and to offer guidance and support. "It's important to know history, because the more you know about history, the more you know about yourself," King said. "But more importantly, it helps you shape the future." I had one last question for King. The graduation ceremony is a really big deal at Cal State L.A., I told her. Many of the grads are first-generation college students, and the achievement is celebrated by cheering extended families. Will you walk the stage in the spring in cap and gown? She smiled. "If I can," she said, "I will." Sign up for Essential California for news, features and recommendations from the L.A. Times and beyond in your inbox six days a week. This story originally appeared in Los Angeles Times.
Yahoo
22 minutes ago
- Yahoo
Two more people arrested in connection with murders of great-grandparents in St Helens house fire
Two more people have been arrested in connection with the murders of great-grandparents who died in an arson attack at their home in St Helens. Eric Greener, 77, and Sheila Jackson, 83, died after the blaze in the early hours of 15 July. On Thursday, Merseyside Police said that a 33-year-old man from Aigburth was arrested on suspicion of conspiracy to murder and possession of cannabis. He has been taken to a police station for questioning. A 36-year-old woman from Everton was arrested on suspicion of conspiracy to murder and conspiracy to commit arson. She has been conditionally bailed. Lee Owens, 46, of no fixed address, has been charged with two counts of murder and arson with intent to endanger life. He has been remanded in custody and will appear at Liverpool Crown Court on 28 November. Detective Chief Inspector Steve McGrath said: "Progress is being made but I would also like to take this opportunity to ask for anyone who holds information to come forward if you haven't yet done so. "Please do not assume that we already know something which could be a vital piece of the jigsaw. Let us make the assessment and take the appropriate action." A 31-year-old man from St Helens who was arrested on suspicion of murder remains on conditional bail. A 48-year-old woman of no fixed abode; a 53-year-old woman from Anfield and a 45-year-old man from Liverpool, who were all arrested on suspicion of conspiracy to murder and conspiracy to commit arson, have been conditionally bailed.